Twitxy Saved

Valeria Fumagalli

@ValeFuma91

Immunologist | Working lifestyle based on scientific curiosity and passion for research | Lover of life and its flavours.
Joined April 2022
79 Following 129 Followers 54 Posts

Latest posts 5

Valeria Fumagalli @ValeFuma91
Are you interested in HBV?
Let's look at our 'Year in Review' in @NatRevGastroHep to see the main discoveries in 2024 that redifine HBV-specific CD8+ T cell dysfunction.
Note: Disfunction is different from exhaustion!
Iannacone Lab @iannaconelab Nov 19, 2024
Excited to share our "Year in Review" perspective in @NatRevGastroHep, where @ValeFuma91 and I highlight key advances in understanding #HBV infection from 2024! We focused on three groundbreaking studies that redefine HBV-specific CD8+ T cell dysfunction:
1️⃣ Heim et al. (@NatImmunol) unveiled a distinct subset of HBV-specific CD8+ T cells that, while attenuated, retain cytotoxic potential. They showed TGFβ signaling maintains this state, suggesting TGFβ inhibition could restore antiviral function.
🔗 nature.com/articles/s4159…
2️⃣ Bosch et al. (@Nature) demonstrated how liver sinusoidal endothelial cells (LSECs) suppress HBV-specific CD8+ T cell activation via cAMP–PKA signaling. This delicate balance limits viral clearance but prevents excessive liver damage.
🔗 nature.com/articles/s4158…
3️⃣ Andreata et al. (@CellCellPress), from our group, showed that co-signaling modulation via 4-1BB agonism reinvigorates dysfunctional HBV-specific CD8+ T cells, providing a promising alternative to checkpoint blockade.
🔗 cell.com/cell/fulltext/…
These studies underscore the complexity of CD8+ T cell dysfunction in chronic HBV and spotlight new therapeutic opportunities, from 4-1BB agonists to TGFβ inhibitors. 🧪🧬
Special thanks to @ERC, @AIRC_it, @EMBO_YIP, @ArmeniseHarvard, @SanRaffaeleMI, @MyUniSR, @ICE_HBV, @HepBFoundation, @EASLnews, and @AASLDtweets for supporting this field of research! nature.com/articles/s4157…
View quoted post on X
Valeria Fumagalli @ValeFuma91
Interesting review about the roles of IFNs during SARS-CoV-2 infection! From a great lab @Lo_Zanzi
Don't miss it!
Ivan Zanoni Verified account @Lo_Zanzi May 22, 2024
#InterferonPower! #FriendsOrFoes?! 💥 Excited 💥 to share our latest work @ Current Opinion In #Immunology! Enjoy the #OpenAccess link to find out everything we know about #Interferons in #COVID19 in adults, elderly, & kids, & how #IFNs impacts #LongCOVID! sciencedirect.com/science/articl…
View quoted post on X
Valeria Fumagalli @ValeFuma91
Happy to share our latest work on SARS-CoV-2.
Great team-work of the @iannaconelab
Are we protected towards a heterologous SARS-CoV-2 challenge after a prior vaccination or infection?
YES, even in the absence of antibodies!
How is it possible?
Read the paper and find the answer
Iannacone Lab @iannaconelab Mar 14, 2024
💥 Exciting News! Our latest research is now online @NatImmunol! Discover how prior infection or vaccination provides antibody-independent protection against heterologous SARS-CoV-2 challenge! 🧵🔬 (1/10)
nature.com/articles/s4159…

2/ 🛡️ Shifting paradigms, our research highlights T cells' paramount role in defending against COVID-19 beyond antibody responses. Even in the complete absence of antibodies, T cells stand guard.

3/ 🧬 Our study utilized advanced mouse models, including a pioneering human/mouse ACE2 hybrid, to unveil that T cell immunity effectively counters various SARS-CoV-2 strains without relying on antibodies.

4/ 💪 Highlight of our findings: CD8+ T cells are crucial for combating severe infections, complemented by CD4+ T cells in less severe cases. The linchpin? Interferon-gamma (IFN-γ), driving this antibody-independent protection.

5/ 🔄 Demonstrated across models mimicking the spectrum of disease severity, this research shows that T cells not only prevent disease but also curb early SARS-CoV-2 replication.

6/ 📚 Building on the collective efforts of many in the field, our study underscores T cells' essential and sufficient role in safeguarding against SARS-CoV-2, reinforcing the critical importance of cellular immunity in the fight against COVID-19.

7/ 🌐 While our findings support vaccine strategies enhancing T cell responses, it's essential to acknowledge the efficacy of current vaccines in eliciting T cell immunity. We advocate for evaluating T cell responses alongside antibodies to fully assess vaccine effectiveness and explore targeted strategies for optimal T cell activation.

8/ 🙌 A heartfelt thank you to our incredible team and collaborators, especially lead author @ValeFuma91, along with key contributors Micol Ravà and Davide Marotta, as well as our collaborators Luca Guidotti, Marco Bianchi, and Raffaele De Francesco.

9/ 🌟Appreciation to our supporters @ERC, @AIRC_it, @EMBO_YIP, @ArmeniseHarvard, @mur_gov_, @SanRaffaeleMI, @MyUniSR, Fondazione SAME, Fondazione Prossimo Mio. Thanks also to our reviewers and Nick Bernard for their invaluable contributions to our journey.

10/ Dive deeper into our study to grasp its impact on immunology and future vaccine development. We're eager to hear your thoughts and engage in discussions! nature.com/articles/s4159…. Your feedback and insights are invaluable. 📖💭
View quoted post on X
0 replies 0 reposts 18 likes 514 views View on X
Valeria Fumagalli @ValeFuma91
Very nice and complete review on liver and intra-hepatic adaptive immune responses!! Take a look!
Great work of Keigo @CristianBecc @frarro1 @iannaconelab
Thrilled to share our latest review on priming and maintenance of intrahepatic immune responses during infection! Huge thanks to @iannaconelab @CristianBecc and Keigo Kawashima, honored to have collaborated with you all.
View quoted post on X